替米沙坦联合阿托伐他汀治疗糖尿病肾病的疗效分析

Therapeutic Analysis of Telmisartan and Atorvastatin for Patients with Diabetic Nephropathy

目的:探讨替米坦联合阿托伐他汀治疗糖尿病肾病(DN)的疗效及机制。方法:选择糖尿病肾病60例,随机分为治疗组和对照组各30例,对照组单用替米沙坦治疗,治疗组应用替米沙坦联合阿托伐他汀治疗,疗程6个月。治疗前后观察TC、TG、尿微量白蛋白(MALB)、24h尿蛋白、Scr、BUN、C-反应蛋白、IL-6的值。结果:治疗前,两组TC、TG、尿微量白蛋白(MALB)、24h尿蛋白、Scr、BUN、C-反应蛋白、IL-6的值比较无明显差异(P>0.05),治疗6月后,与治疗前比较,除TC、TG外,两组患者的尿微量白蛋白(MALB)、24h尿蛋白、Scr、BUN、C-反应蛋白、IL-6的值下降(P<0.01),治疗组的TC、TG、尿微量白蛋白(MALB)、24h尿蛋白、Scr、BUN、C-反应蛋白、IL-6值较对照组低,差异有统计学意义(P<0.01)。结论:采用替米沙坦和阿托伐他汀治疗糖尿病肾病具有降血脂、减少尿蛋白、改善肾功能、延缓病情进展的作用。

Objective：To investigate effects of telmisartan and atorvastatin on patients with diabetic nephropathy（DN） and relative mechanism.Methods：60 cases of patients with DN were divided into two groups：Control group（n=30） and Treated group（n=30）,patients in Control group treated with telmisartan,patients in Treated group treated with telmisartan and atorvastatin.Before of treatment and 6 months after treatment,values of total cholesterol（TC）,triglyceride（TG）,microalbuminuria（MALB）,24 hours urokinase protein（UP）,serum creatinine（Scr）,blood urea nitrogen（BUN）,C reactive protein（CRP）,interleukin-6（IL-6） in all patients were measured and compared.Results：Before treatment,values of TC,TG,MALB,24 h UP,Scr,BUN,C RP,IL-6 in patients showed no diffence between treated group and control group（P〉0.05）.Six months after treatment,values of TC,TG,MALB,24 h UP,Scr,BUN,C RP,IL-6 in Treated group were lower than those Control group（P〈0.01）,and values of MALB,24 h UP,Scr,BUN,C RP,IL-6 in the two groups were lower than those before treatment（P〈0.01）.Conclusion：Telmisartan and atorvastatin have protective effects on patients with DN,and can lower blood lipids and urokinase protein and improve renal function.